Related Experiment Video
Updated: Jun 26, 2026
11:09
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
39.2K
A 2035 Clinical Research Vision and Roadmap for High-Risk Neuroblastoma
Lucas Moreno1,2,3, Steven G Dubois4, Nicholas Bird5
1Vall d'Hebron Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Pediatric Blood & Cancer
|April 5, 2025
Summary
High-risk neuroblastoma in children still has poor outcomes despite anti-GD2 antibody therapy. Future efforts focus on novel frontline agents to improve cure rates and reduce long-term side effects.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Cancer Research
Background:
- Outcomes for high-risk neuroblastoma remain poor.
- Current anti-GD2 antibody therapy has limitations.
- Survivors often experience long-term sequelae.
Purpose of the Study:
- Review lessons learned in neuroblastoma treatment.
- Identify challenges in current high-risk neuroblastoma therapy.
- Propose a vision for improving frontline treatment strategies.
Main Methods:
- Expert review and consensus building.
- Analysis of current treatment landscape.
- Identification of future research directions.
Main Results:
- Current therapies show limited efficacy for high-risk neuroblastoma.
- Significant challenges exist in translating research to frontline care.
- A need for novel agents and improved therapeutic strategies is evident.
Conclusions:
- Future neuroblastoma treatment requires global collaboration.
- Incorporating novel biomarkers is crucial for personalized therapy.
- Strengthened regulatory interaction is needed to expedite new agent approvals.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...